Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-20

FDA Approved: CABTREO — Original Application (Bausch Health US LLC)

View source ↗

Summary

FDA approves CABTREO, a triple-combination topical acne medication containing clindamycin phosphate, benzoyl peroxide, and adapalene, for the treatment of acne …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cabtreo

Snippet

ORIG AP for CABTREO (CLINDAMYCIN PHOSPHATE/BENZOYL PEROXIDE/ADAPALENE)